Investor Relations CEVEC Pharmaceuticals GmbH has recently completed a new financing round including private investors, the KfW bank group and Sparkasse KölnBonn. Members of the financial community and private investors seeking additional information on CEVEC Pharmaceuticals GmbH are encouraged to contact Dr. Rainer Lichtenberger: lichtenberger@cevec-pharmaceuticals.com

   Using CEVEC's proprietary technology, primary human amniocytes have been immortalized by adenoviral genetic E1/pIX functions and selected for highly efficient CAP (CEVEC's Amniocyte Production) Cell Lines. CAP (CEVEC's Amniocyte Production) Cell Lines contain adenovirus type 5 nucleotide sequence 505-4079 including the E1 genes and the entire pIX sequence.